Success Stories: North America Immigration Law Group Got 2 Cases Approved (NIW + I-485 ) for a Bangladeshi Postdoctoral Associate in the Field of Biomedical Science

Client’s Testimonial:

“We are so grateful and blessed to work with you. We thank you so much for your all help throughout our application. We wish your continuous success.”

On August 7^th, 2021, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Associate in the Field of Biomedical Science (Approval Notice).

General Field: Biomedical Science

Position at the Time of Case Filing: Postdoctoral Associate

Country of Origin: Bangladesh

State of Residence at the Time of Filing: Florida

Approval Notice Date: August 7^th, 2021

Processing Time: 11 months

Case Summary:

With millions of patients only in the United States suffering from different varieties of cancer, the proposed endeavor of our client to continue investigation into understanding molecular mechanisms associated with altered cancer metabolism and metabolic dysfunction in child malnutrition and to identify common unknown metabolic liabilities correlating with tumor microenvironmental components in order to illuminate cancer metabolic dark matter and discover novel anti-cancer metabolic targets, immediately attracted our attention. So, when he wanted to file for an NIW (National Interest Waiver) and I-485, we helped him by customizing his application to USCIS.

North America Immigration Law Group specializes in NIW petitions and we have an impressive 25,000+ approval record. This gives us an edge in deciding the most suitable legal strategies depending on the client’s background. This is why after thoroughly checking the background information, we went ahead to help the client in filing a customized petition. We were able to get him an NIW approval in a relatively short period of 11 months. We made this possible by including some of the following information in the application.

That his research has resulted in 15 peer-reviewed journal articles (9 of them first-authored), and one first-authored book chapter. Moreover, these papers have been published in the top journals of this field. He has published these papers in no fewer than 6 highly ranked peer-reviewed journals.
His research has also gone on to influence his peers. That is, his publications have been cited a total of 162 times according to Google Scholar.
He has completed at least 5 peer reviews to date. Since only the most highly esteemed researchers in the field are invited to evaluate the work of their peers, especially in authoritative journals like these, his position as a preeminent scholar is clear.
In recognition of the value and importance of his work, his research has been granted funding by the NIH, Bankhead-Coley Cancer Research Program, James and Esther King Biomedical Research Program, and Florida Breast Cancer Research Foundation. These institutions are dedicated to addressing substantial public health concerns within the U.S.

This is why one of the independent advisory opinions, that we suggested him to obtain said the following about him:

“The benefits of [the client’s] research on the molecular mechanisms associated with altered cancer metabolism directly translates to positive patient outcomes for the millions of Americans afflicted with cancer.”

We thus wish him the best in all his future endeavors and we are assured that he will help progress the field in various novel ways. We are certain that his work would have a significant and tangible benefit to the national healthcare system, individual economic well-being, and national public health.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.